Asset Details
Do you wish to reserve the book?
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Do you wish to request the book?
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
2024
Overview
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer progression. For these patients, while subsequent immunotherapies that either target a different axis of immune biology or non-immune combination therapies are reasonable treatment options, the lack of predictive biomarkers to follow-on agents is impeding progress in the field. This review summarizes the current knowledge of mechanisms driving resistance to PD-(L)1 therapies, the state of biomarker development along this axis, and inherent challenges in future biomarker development for these immunotherapies. Innovation in the development and application of novel biomarkers and patient selection strategies for PD-(L)1 agents is required to accelerate the delivery of effective treatments to the patients most likely to respond.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ B7-H1 Antigen - antagonists & inhibitors
/ Biomarkers, Tumor - metabolism
/ Cancer
/ Cells
/ Disease
/ Failure
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - pharmacology
/ Immune Checkpoint Inhibitors - therapeutic use
/ Ligands
/ Melanoma
/ Patients
/ Response Evaluation Criteria in Solid Tumors - RECIST
/ Review
/ Tumors
